Watkin Jones plc (AIM:WJG), a leading UK developer and constructor of multi occupancy property assets, with a focus on the student accommodation sector, has told DirectorsTalk its maiden annual results
Stephen O’Hara, CEO of OptiBiotix LON:OPTI, said to DirectorsTalk: “Christina’s experience of building sales in her own business by developing relationships with food ingredient manufacturers and major retailers brings new
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that Robert Dickey IV has been appointed as Chief Financial Officer. Mr.
Edenville Energy plc (AIM: EDL) is pleased to announce that the second stage of the Environmental and Social Impact Assessment (“ESIA”) for Company’s integrated coal to power project in western
Nigel Keen, Deltex Medical LON:DEMG Chairman, said: “Deltex made good progress in 2016. Growing sales traction in the USA, our main focus market, and in other International markets, together with
The UK has a serious skills shortage when it comes to cyber security, and the chasm between supply and demand for expertise is widening at an alarming rate. The results
Gresham House Strategic’s Graham Bird discusses how 2016 went for them, standout investments, his view on prospects for the year, interesting sectors and stocks he likes the look of for 2017 in this exclusive interview with DirectorsTalk
Researchers have found that a snowflake-like fractal design, in which the same pattern repeats at smaller and smaller scales, can increase graphene’s inherently low optical absorption. The results lead to
Northland Capital partners view on Evgen Pharma PLC LON:EVG: First Patient Dosing in this trial represents another major milestone for Evgen. With two Phase 2 trials now dosing patients and
Final results are broadly in line with our revised forecasts on most headline levels in what proved to be a difficult year for the Group. That said, it has significantly
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
